Research Medical

ASLIHAN TURHAN, PH.D.

www.linkedin.com/in/aslihanturhan

● Cell: 917-***-**** ● E-mail: actc81@r.postjobfree.com My 15+ years of expertise in immunology research/translational medicine, in therapeutic several areas provided me the following strengths:

• Scientific Competence: Research experience in drug target/biomarker identification and validation furnished me with the necessary skills to plan, execute, and troubleshoot decisional experiments.

• Scientific Communication: Publications in top-tier journals have been invited as a speaker to national and international conferences. I have excellent ability to communicate complex scientific concepts to all levels of people.

• Personable and Adaptable: Excellent interpersonal skills providing me the ability to develop great relations with KOLs and other experts in the field. I have a strong sense of timing and organization skills.

• Teaching Skills: Both technical teaching experience as well as teaching experience in Medical PROFESSIONAL EXPERIENCE

MEEI/Harvard Medical School 2015-2016

Visiting Scientist

Continued working on the identification of targets on DC trafficking in steady state and in inflammation. Harvard Medical School 2002 – 2013

Instructor

Conceived and led target drug/biomarker discovery projects focused on inflammatory diseases. Developed new research hypotheses and established imaging techniques in colon and cornea. Identified targets and developed project concepts on DC trafficking in steady state and inflamed cornea:

• Designed and directed experiments to identify the mechanism of action and efficacy biomarkers for target blockade using in vitro and in vivo characterization.

• Identified a target molecule for drug discovery in the inflamed cornea.

• Worked on the development and execution of biomarker identification strategy and in optimizing groups effectiveness in achieving project objectives on time.

• Set up cell- based screening assays and ensured optimal biomarker analysis and data collection from the samples.

• Led biomarker assay development for clinical sample testing in early stage clinical programs using immunoassay, IHC, FISH, and imaging technologies

• Hands on experience on detection of T and B lymphocytes subgroups

• Built collaborative relationships with KOLs specializing in immune-related diseases.

• Published article as first author and co-authored multiple articles in peer-reviewed journals.

• Presented research findings at national and international conferences.

• Reviewed manuscripts for peer-reviewed journals as well as grant applications for the related to corneal immunology / imaging.

Submitted a provisional patent application for Methods for treating corneal and conjunctival inflammation and inflammatory disorders.

Conducted research on sickle cell disease in human subjects:

• Prepared a research protocol for human subjects and participated in the research.

• Coordinated between CRO and the clinical team as needed.

• Prepared and submitted IRB applications for human studies.

• Identified the contribution of lymphocyte subpopulations to intravascular occlusions.

• Acted as the key scientific liaison with collaborators in research and clinical settings

• Organized activities to facilitate continuous learning

• Presented research progress and latest findings from literature and conferences. Aslihan Turhan, Ph.D. Page 2 of 2

Mount Sinai School of Medicine 1999 – 2002

Postdoctoral Research, Hematology

Conceptualized, designed and led research in Sickle cell vasoocllusion. The research resulted in the breakthrough discovery that the interaction between the sickled red blood cells was not directly with vessel wall endothelial cells but instead there was a leukocyte between endothelial cell and the red cell. Designed, managed and executed clinically translatable research on sickle cell disease.

• Conducted research on intravascular cellular interactions in sickle cell disease.

• Identified drug target candidates associated with vascular occlusion and corneal inflammation.

• Discovered leukocytes as the target cell in and filed a patent application.

• Conducted PK/PD studies in a mouse model of sickle cell disease for IVIg.

• Designed the study treating the sickle cell mouse by injecting IVIG which blocks the adhesion of the leukocyte to the vessel wall and, therefore, avoids vascular occlusions. The study resulted in clinical trial now being conducted.

• Developed intravital imaging technique for imaging leukocyte-vessel wall interactions in a living mouse.

• Built and maintained relationships with KOLs.

Published as the first author in peer-reviewed journals. Submitted a provisional patent application for treatment models for sickle cell disease. TEACHING EXPERIENCE

Boston University Medical School 2002 – 2005

Instructor, Graduate School

Taught courses in immunology to 10 – 14 students. Courses included:

• Molecules to Molecular Therapeutics: The Translation of Molecular Observations to Clinical Implementation

• Sickle cell adhesion: Mechanisms of cell-cell interactions

• EDUCATION & PROFESSIONAL DEVELOPMENT

• Certification •Clinical Marketing, and Management Program- KRIGER International

• Ph.D., Immunology ● Gazi University, Ankara, Turkiye

• Certificate, Clinical Marketing and Management Program●Kriger Research Center

• Ph.D., Molecular Biology ● Hacettepe University, Ankara, Turkiye

• M.Sc., Biochemistry ● Hacettepe University, Ankara, Turkiye SELECTED PRESENTATIONS AND PUBLICATIONS

Position Related Publications:

Invited Speaker:

3rd International Conference and Exhibition on Clinical & Cellular Immunology, September 29 - October 01, 2014 Baltimore, USA Baltimore, USA

Selected Oral Presentations:

1. ARVO 2012, May 1-6, Fort Lauderdale. Oral Session: Corneal Infection and Inflammation Mucosal Addresin Cell Adhesion Molecule (MADCAM-1) Plays a Pivotal Role in Dendritic Cell Recruitment to the Cornea during Inflammation

2. 27th Biennial Cornea Conference, September 30, 2011, Boston Disection of biomarkers involved in homing and egress of DC’s to and from cornea in steady state and in inflammation 3. Comprehensive Sickle Cell Centers Meeting, 2002, High-Dose Intravenous Immunoglobulin Prevents Vaso- Occlusion in Sickle Cell Mice

4. 9th Annual Samuel Bronfman Department of Medicine Research Day, 16 October 2001 Outstanding Basic and Clinical Research Presentations: A Primary Role for Adhesive Leukocytes in Sickle Cell Vascular Occlusion

5. ASH Meeting 2000, Oral Session: Sickle Cell Disease-Basic Investigation Sickle Cell interactions with adherent leukocytes can initiate venular occlusion in Sickle Cell Mice Aslihan Turhan, Ph.D. Page 3 of 3

Selected Publications

1. Aslihan Turhan, Takefumi Yamaguchi, Deshea L. Harris, Ulrich von Andrian, Pedram Hamrah: Pivotal Role of Mucosal Addresin Cell Adhesion Molecule (MADCAM-1) in Dendritic Cell Recruitment to the Cornea during Inflammation (In preparation)

2. Takefumi Yamaguchi, Aslihan Turhan, Deshea L. Harris, Tatiana Ecoiffier, Shizu Ishikawa, James Lederer, Lu Chen, Kazunari Higa, Jun Shimazaki David Alvarez, Ulrich von Andrian, Pedram Hamrah Neurogenic Immune Homeostasis: Peripheral Innervation Maintains Immune Privilege (In preparation)

3. Yamaguchi T., Turhan A., Harris DL., Hu K., Pruss H., von Andrian U., Hamrah P. Bilateral nerve alterations in a unilateral experimental neurotrophic keratopathy model: a lateral conjunctival approach for trigeminal axotomy. PLoS One 2013, 148(8): e70908

4. Takefumi Yamaguchi, Aslihan Turhan, Deshea L. Harris, Kai Hu, Harald Prüss, Ulrich von Andrian, Pedram Hamrah: Bilateral Nerve Alterations in a Unilateral Experimental Neurotrophic Keratopathy Model: A Lateral Conjunctival Approach for Trigeminal Axotomy Research Article PLOS ONE 14 August 2013, DOI 10.1371 5. Aslihan Turhan, Miao Lin, Grace S. Lee, Lino Miele, Akira Tsuda, Moritz Konerding, and Steven J. Mentzer Vascular Microarchitecture of Murine Colitis-Associated Lymphoid Neogenesis Anat Rec (Hoboken). 2009 May; 292(5): 621-32

6. Aslihan Turhan, Akira Tsuda, Moritz Konerding, Miao Lin, Lino Miele, Grace Lee, and Steven J. Mentzer. Effect of Intraluminal Pillars on Particle Motion in Bifurcated Microchannels. In Vitro Cell. Dev. Biol.-Animal 44 (10): 426-433, 2008

7. Aslihan Turhan, Linnea Weiss, Narla Mohandas, Barry S.Coller, Paul S.Frenette Primary Role for Adherent Leukocytes in Sickle Cell Vascular Occlusion: A New Paradigm, PNAS, 99 (5): 3047-3051, 2002 8. Aslihan Turhan, Barry S.Coller, Paul S.Frenette High-Dose Intraveneous Immunoglobulin Prevents Vaso- Occlusion in Sickle Cell Mice Blood, 100(11): 449a, 2002 9. Aslihan Turhan, Pegah Jenap, Pierre Bruhns, Jeffrey V. Ravetch, Barry S. Coller, Paul Frenette Intravenous immunoglobulin prevents vaso-occlusion in sickle mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood, 103 (6): 2397, 2004 BOOK CHAPTERS

1) Trafficking of immune cells in the cornea and ocular surface. Yureeda Qazi, Aslihan Turhan, Pedram Hamrah Ophthalmology, ISBN 978-953-307-803-8

2) Immunology, Aslihan Turhan, Stryer, 6th Edition, (Translation to Turkish) PATENT APPLICATIONS

04/02 “Improved Methods of treating Sickle Cell Disease” by Paul Frenette, Barry Coller and Aslihan Turhan

(United States Patent 200********)

02/13 “Methods for treating corneal and conjunctival inflammation and inflammatory disorders.” By Aslihan Turhan, Pedram Hamrah, Ulrich Von Andrian (Publication number: WO2013126595 A1, International Application no: PCT/US2013/027172).

Contact this candidate